United Therapeutics (UTHR) Other financing activities (2009 - 2026)

United Therapeutics has reported Other financing activities for 18 years, with the latest figure at $68.3 million in Q1 2026.

• Quarterly Other financing activities rose 311.45% year-over-year to $68.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $225.6 million (up 123.15% YoY) and the FY2025 annual result came in at $173.9 million, up 2188.16% from the prior year.
• Other financing activities slipped to $68.3 million in Q1 2026 per UTHR's latest filing, from $99.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $99.0 million in Q4 2025 and troughed at -$84.1 million in Q4 2023.
• A 5-year average of $19.0 million and a median of $18.1 million in 2025 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2023 and 2025: Other financing activities plunged 211.48% in 2023, then surged 99100.0% in 2025.
• Over 5 years, Other financing activities stood at -$27.0 million in 2022, then slumped by 211.48% to -$84.1 million in 2023, then soared by 99.88% to -$100000.0 in 2024, then soared by 99100.0% to $99.0 million in 2025, then sank by 31.01% to $68.3 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $68.3 million, $99.0 million, and $40.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.